What is Wedbush's Forecast for RARE FY2027 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Wedbush cut their FY2027 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Tuesday, July 15th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($1.49) per share for the year, down from their prior estimate of ($1.46). Wedbush currently has a "Neutral" rating and a $34.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

A number of other research analysts have also issued reports on RARE. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Guggenheim reissued a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Morgan Stanley dropped their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Finally, Wells Fargo & Company dropped their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Stock Down 4.0%

RARE stock traded down $1.10 during mid-day trading on Thursday, reaching $26.31. The company had a trading volume of 3,904,088 shares, compared to its average volume of 977,685. Ultragenyx Pharmaceutical has a one year low of $26.00 and a one year high of $60.37. The stock's 50-day simple moving average is $35.65 and its two-hundred day simple moving average is $38.20. The stock has a market capitalization of $2.49 billion, a P/E ratio of -4.47 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The firm had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. During the same quarter last year, the business earned ($2.03) earnings per share. The business's revenue for the quarter was up 28.0% compared to the same quarter last year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 3,167 shares of company stock valued at $118,824. Insiders own 5.50% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 669 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $57,000. Finally, Headlands Technologies LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $59,000. 97.67% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.